NDRA (ENDRA Life Sciences) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is ENDRA Life Sciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ENDRA Life Sciences's Free Cash Flow for the three months ended in Sep. 2024 was $-1.66 Mil. ENDRA Life Sciences's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, ENDRA Life Sciences's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, ENDRA Life Sciences's current FCF Yield % is -352.01%.

The historical rank and industry rank for ENDRA Life Sciences's FCF Margin % or its related term are showing as below:

During the past 10 years, the highest FCF Margin % of ENDRA Life Sciences was -69.29%. The lowest was -130033.33%. And the median was -299.11%.

NDRA's FCF Margin % is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: -5.38
* Ranked among companies with meaningful FCF Margin % only.

ENDRA Life Sciences FCF Margin % Historical Data

The historical data trend for ENDRA Life Sciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ENDRA Life Sciences FCF Margin % Chart

ENDRA Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

ENDRA Life Sciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of ENDRA Life Sciences's FCF Margin %

For the Diagnostics & Research subindustry, ENDRA Life Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ENDRA Life Sciences's FCF Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ENDRA Life Sciences's FCF Margin % falls into.

ENDRA Life Sciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ENDRA Life Sciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-9.583	/	0
	=	%

ENDRA Life Sciences's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-1.657	/	0
	=	%

ENDRA Life Sciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of ENDRA Life Sciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ENDRA Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ENDRA Life Sciences Inc (NAS:NDRA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3600 Green Court, Suite 350, Ann Arbor, MI, USA, 48105-1570

Website

https://www.endrainc.com

ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Executives

Michael Milos Thornton	officer: Chief Technology Officer	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Anthony Digiandomenico	director	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Alexander Y Tokman	director	C/O MICROVISION, INC., 6222 185TH AVENUE NE, REDMOND WA 98052
Francois Roger Michelon	director, officer: Chief Executive Officer	430 N. JUNO LANE, JUNO BEACH FL 33406
Lou Basenese	director	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Irina Pestrikova	officer: Senior Director, Finance	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Renaud Bertrand Maloberti	officer: Chief Commercial Officer	10 ACORN WAY, GEORGETOWN MA 01833
David R. Wells	officer: Chief Financial Officer	2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Michael Harsh	director	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105
Longboard Capital Advisors, Llc	10 percent owner	9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212
Brett Conrad	10 percent owner	1312 CEDAR ST., SANTA MONICA CA 90405
Sanjiv Sam Gambhir	director	3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105